Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Short Interest Update

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 1,700 shares, a growth of 88.9% from the February 13th total of 900 shares. Based on an average daily volume of 11,800 shares, the short-interest ratio is currently 0.1 days. Currently, 0.5% of the shares of the stock are short sold.

Scinai Immunotherapeutics Trading Up 0.5 %

Shares of Scinai Immunotherapeutics stock opened at $3.35 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.16 and a quick ratio of 1.16. Scinai Immunotherapeutics has a 1 year low of $2.23 and a 1 year high of $8.92. The firm has a market cap of $2.85 million, a PE ratio of -0.01 and a beta of 2.36. The company has a 50 day simple moving average of $3.46 and a two-hundred day simple moving average of $3.48.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.